dpp 4 inhibitor and glp 1 receptor agonist combination Dipeptidyl Peptidase Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus DPP-4 inhibitors for type 2

A Wilcoxon matched-pairs test was used to assess for differences between groups

Griffin et al

Heinrich, T

Koskas M, Amant F, Mirza MR, Creutzberg CL

In addition, the design of lymphatic delivery systems has progressed from simple systems that rely on passive lymphatic access to sophisticated structures that use nanotechnology to mimic endogenous macromolecules and lipid conjugates that 'hitchhike' onto lipid transport processes

Ongoing Research and Expansion Pharmaceutical companies continue researching new uses for GLP-1 medications, including potential benefits for cardiovascular health and other chronic conditions